hyperplasia of mammary glands
Conditions
Interventions
observation group:Ruhe Sanjie tablet
control group:placebo
Sponsors
Dongzhimen Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Meet the above diagnostic and syndrome differentiation criteria; (2) Women aged 18-60; (3) Patients who have not received drug treatment related to breast hyperplasia in the past 1 month and have not used hormone drug treatment in the past 6 months; (4) Not participating in other related clinical trials; (5) Sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with acute breast inflammation and breast fibroadenoma; (2) There is a tendency of breast cancer or breast malignancy, or a history of breast cancer; (3) Patients with serious cardiovascular, cerebrovascular, hematopoietic and other primary diseases and mental diseases; (4) Pregnant or lactating women and those who have a pregnancy plan in the past 3 months; (5) Patients with long-term use of endocrine, anti-inflammatory analgesic, antipsychotic drugs; (6) Menstrual cycle is not according to the monthly regularity of the tide, such as polycystic ovary syndrome, uterine fibroids; Taking contraceptives and sex hormone drugs; (7) Allergic to the test drug and its ingredients; (8) The subjects are unwilling to participate in the study or do not cooperate with treatment; (9) The researcher considers it inappropriate to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain and mass score improvement rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number, texture, size and scope of breast mass changed;Breast color B-ultrasound detection;Hamilton Anxiety and Depression Scale;TCM syndrome score of accompanying symptoms;Sex hormone test; | — |
Countries
China
Contacts
Public ContactGAO Xiang
Dongzhimen Hospital Beijing University of Chinese Medicine
Outcome results
None listed